<Page>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: JULY 26, 2001
ISONICS CORPORATION
(Name of small business issuer as specified in its charter)
CALIFORNIA 001-12531 77-0338561
State of Commission File IRS Employer
Incorporation Number Identification No.
5906 MCINTYRE STREET, GOLDEN, COLORADO 80403
Address of principal executive offices
303-279-7900
Telephone number, including
Area code
NOT APPLICABLE
Former name or former address if changed since last report
<Page>
ITEM 5 - OTHER EVENTS
Isonics Corporation (NasdaqSC:ISON/ISONW) (OTCBB:ISONL/ISONZ) and
(Frankfurt:IO9) a leader in the development of isotopically pure silicon-28
announced today that holders of more than the required two-thirds of the
total outstanding Class B and Class C warrants have consented to a change in
the terms of the Class B warrant, which among other things, fixes the Class B
warrant exercise price at $1.50 (subject only to normal dilution adjustments
as described in the warrant agreement).
The change eliminated the section of the warrant agreement that
provided for a price adjustment to $0.75 from $1.50 to the extent that a
warrant holder submitted a warrant for exercise at a time when a registration
statement relating to such exercise was not current and in effect after June
13, 2001. Holders of publicly traded Class B warrants should note that there
is and has been a registration statement in effect and current related to
those warrants and therefore, their warrants were never subject to such
exercise price adjustment. This change makes the terms of the publicly traded
warrants consistent with the Class B warrants sold in the December placement
with the result being that no Isonics Class B warrants may be exercised at a
price other than $1.50.
Isonics will shortly mail written notification to all of our Class B
and Class C warrant holders as required by SEC rules. This amendment will
become effective 30 days after that mailing.
Isonics is a world leader in isotopically engineered materials and
produces isotopically pure silicon-28 chemicals and wafers for the
semiconductor industry. Isonics also markets and sells stable isotopes for
the health care industry such as carbon-13 for diagnostic breath tests and
drug design, and oxygen-18 for positron emission tomography (PET) imaging.
Stable isotopes can be thought of as ultra pure materials. For additional
information visit www.isonics.com.
Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein. Further, the
Company operates in industries where securities values may be volatile and may
be influenced by regulatory and other factors beyond the Company's control.
Other important factors that the Company believes might cause such differences
are discussed in the risk factors detailed in the Company's 10-KSB for the year
ended April 30, 2000, and its quarterly report on Form 10-QSB for the nine
months ended January 31, 2001, both as filed with the Securities and Exchange
Commission, which include the Company's cash flow difficulties, dependence on
significant customers, and rapid development of technology, among other risks.
In assessing forward-looking statements contained herein, readers are urged to
carefully read all cautionary statements contained in the Company's filings with
the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, on the 27th day of July 2001.
ISONICS CORPORATION
By: /s/ James E. Alexander
------------------------------
James E. Alexander
President and Chief Executive
Officer